Novel oral anticoagulants: an ENT surgeon’s pocket reference tool

Rate this item
(0 votes)

Abstract

Introduction: Novel oral anti-coagulants (NOACs) are set to become increasingly common in ENT patients. January 2015 NICE guidelines recommend rivaroxaban for up to 1 year after a myocardial infarction. This review sets out a guide to managing the new anticoagulants in acute and elective ENT patients.

Methods: Medline/ EMBASE searches and reviews of specialist society guidelines and expert recommendations were conducted.

Results: Limited RCT evidence exists to date on peri-operative management and emergency reversal. We have therefore condensed society guidelines and expert recommendations to create a succinct, practical guide to the peri-operative and emergency management of these patients.

Conclusion: Novel anticoagulants are poised to take over from warfarin (at least 1% of the UK adult population) for most indications. Yet in practice most surgeons have had limited experience with them. This review and ‘surgeon’s guide’ aims to set out a best-evidence foundation from which to respond to the emerging challenge.

Additional Info

  • Authors: Y Kamhieh & H Fox
  • Keywords: novel oral anticoagulants – rivaroxaban – apixaban – dabigatran – peri-operative – elective surgery - emergency surgery – epistaxis – bleeding – haemorrhage
Read 31 times Last modified on Tuesday, 24 October 2017 15:18

Leave a comment

Make sure you enter the (*) required information where indicated. HTML code is not allowed.

Search

Member Login

          Forgot login? | Register

BBC News Feed

Get in touch

Tel:
+44 207 637 3544

Email:
This email address is being protected from spambots. You need JavaScript enabled to view it.

Address:
The Otorhinolaryngologist,
73 Newman Street, London
W1T 3EJ, 
UK

 

Rila Publications Ltd Ethics Policy